CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers ...
Feb 18, 2021
0
12